SOCM
SR One Capital Management Portfolio holdings
AUM
$691M
1-Year Est. Return
58.87%
1 Year Est. Return
+58.87%
AUM
$691M
AUM Growth
+$230M
(+50%)
Holding
13
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arcellx
ACLX
$3.75B
| $193M | 27.86% |
2,346,630
|
|
||
2
CRISPR Therapeutics
CRSP
$5.36B
| $132M | 19.11% |
2,038,763
+989,812
|
|
||
|
ZBIO
3
Zenas BioPharma
ZBIO
$1.97B
| $109M | 15.77% |
4,911,539
|
|
||
4
Mineralys Therapeutics
MLYS
$3B
| $80.2M | 11.59% |
2,113,933
-1,014,000
|
|
||
5
Oric Pharmaceuticals
ORIC
$795M
| $54.2M | 7.84% |
4,514,929
|
|
||
6
Design Therapeutics
DSGN
$557M
| $49.1M | 7.11% |
6,526,476
|
|
||
7
ARS Pharmaceuticals
SPRY
$1.05B
| $40.3M | 5.83% |
4,012,903
|
|
||
|
ORKA
8
Oruka Therapeutics
ORKA
$1.53B
| $8.28M | 1.2% |
430,330
|
|
||
|
ALMS
9
Alumis Inc
ALMS
$1.17B
| $7.82M | 1.13% |
1,959,896
|
|
||
10
Nkarta
NKTX
$126M
| $6.9M | 1% |
3,333,333
|
|
||
11
Oculis Holding
OCS
$1.23B
| $5.67M | 0.82% |
322,500
|
|
||
12
enGene Holdings
ENGN
$578M
| $5.11M | 0.74% |
747,750
|
|
||
13
KALA BIO
KALA
$6.97M
| – | – |
-598,940
|
|